Phenylethylidenehydrazine dimers and methods of using same
AssigneeNeurawell Therapeutics
InventorsMagid Abraham, Mark A. Ashwell, Steve Stahl
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for the treatment of treatment-resistant depression and other psychological disorders. In particular, the invention provides phenylethylidenehydrazine dimers, and methods, devices, and kits that incorporate the dimers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Claims30
A pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure represented by a formula:
- wherein each of R1a, R1b, R1c, R1d, R1e, R1a′, R1b′, R1c′, R1d′, and R1e′ is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
- wherein each of R2a, R2a′, R2b, and R2b′ is independently selected from hydrogen, halogen, —OH, —NH2, C1-C4 alkyl, and C2-C4 alkenyl;
- and
- wherein each of R3 and R3′ is independently selected from hydrogen and C1-C4 alkyl,
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
(canceled)
7-9. (canceled)
(canceled)
16-22. (canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising a therapeutically effective amount of a compound having a structure represented by a formula:
- wherein each of Ria R1b, We, R1d, R1e, R1a′, R1b′, R1c′, R1d′, and R1e′ is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
- wherein each of R2a, R2a′, R2b, and R2b′ is independently selected from hydrogen, halogen, —OH, —NH2, C1-C4 alkyl, and C2-C4 alkenyl;
- and
- wherein each of R3 and R3′ is independently selected from hydrogen and C1-C4 alkyl,
- or a pharmaceutically acceptable salt thereof, and an antidepressant, a biocompatible polymer, and a pharmaceutically acceptable carrier.
The pharmaceutical composition of claim 0, wherein the antidepressant is buspirone.
30-35. (canceled)
A method for treating a psychological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound having a structure represented by a formula:
- wherein each of R1a, R1b, R1c, R1d, R1e, R1a′, R1b′, R1c′, R1d′, and R1e′ is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
- wherein each of R2a, R2a′, R2b, and R2b′ is independently selected from hydrogen, halogen, —OH, —NH2, C1-C4 alkyl, and C2-C4 alkenyl;
- and
- wherein each of R3 and R3′ is independently selected from hydrogen and C1-C4 alkyl,
- or a pharmaceutically acceptable salt thereof.
The method of claim 0, wherein the compound is:
The method of claim 0, wherein the method further comprises administering an antidepressant.
39-49. (canceled)
51-53. (canceled)
55-74. (canceled)
Dependencies are inferred from the claim text.